Expression of minichromosome maintenance MCM6 protein in meningiomas is strongly correlated with histologic grade and clinical outcome.
The 2007 World Health Organization histologic grading of meningiomas is associated with recurrence and clinical outcome. However, distinction of grade I from grade II (atypical) meningiomas can be challenging. In the World Health Organization classification, there are 4 parameters on the basis of which grade II status can be determined: mitotic rate, cytoarchitectural features, brain invasion, and/or histologic subtype. Furthermore, this classification fails to detect grade I recurrent meningiomas, for which other prognostic criteria would be needed. The aim of this study was to evaluate the respective value of several markers involved in cell cycle as effective tools to predict recurrence. This retrospective study was based on a series of 59 meningiomas (grade I: 32 of 59, grade II: 27 of 59, all harboring ≥4 mitoses/1.6 mm), analyzed with the following immunohistochemical markers: MCM6, Ki-67, PHH3, cyclin D1, and p53. We found a significant correlation between histologic grade and mean labeling index for MCM6 (grade I: 21.8% vs. grade II: 65.8%; P<0.001), Ki-67 (3.2% vs. 16.9%; P<0.001), PHH3 (0.7‰ vs. 2.8‰; P<0.001), cyclin D1 (50.4% vs. 70.0%; P=0.005), and p53 (17.3% vs. 32.4%; P=0.017). Histologic grading and mitotic index were correlated with progression-free survival (P=0.010 and P=0.020, respectively). A nearly linear correlation was found between progression-free survival and staining for MCM6 (P<0.001), Ki-67 (P=0.003), and PHH3 (P=0.037) but not for cyclin D1 (P=0.400) and p53 (P=0.758). The interobserver agreement coefficients for MCM6, Ki-67, PHH3, cyclin D1, and p53 were, respectively, 0.97 (95% confidence interval, 0.95-0.98), 0.93 (0.89-0.96), 0.81 (0.70-0.88), 0.90 (0.83-0.94), and 0.84 (0.73-0.90). In conclusion, because of its strong level of expression and sharp difference in labeling index between indolent and recurrent tumors, MCM6 is the most efficient marker to identify tumors with a high risk of recurrence.
Department of Pathology, Inserm U954, Medical Faculty of Nancy, France. g.gauchotte@chu-nancy.fr
Guillaume
G
Gauchotte
Charlène
C
Vigouroux
Fabien
F
Rech
Shyue-Fang
SF
Battaglia-Hsu
Marc
M
Soudant
Catherine
C
Pinelli
Thierry
T
Civit
Luc
L
Taillandier
Jean-Michel
JM
Vignaud
Aude
A
Bressenot
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D018797:Cell Cycle Proteins / Q000096:biosynthesis* / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008579:Meningioma / Q000097:blood / Q000378:metabolism* / Q000473:pathology*; D008875:Middle Aged; D064151:Minichromosome Maintenance Complex Component 6; D060787:Neoplasm Grading; D011379:Prognosis; D012189:Retrospective Studies
D015415:Biomarkers; D018797:Cell Cycle Proteins; C103258:MCM6 protein, human; D064151:Minichromosome Maintenance Complex Component 6